Filing Details
- Accession Number:
- 0001209191-24-001067
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-05 18:30:33
- Reporting Period:
- 2024-01-04
- Accepted Time:
- 2024-01-05 18:30:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1741830 | Kronos Bio Inc. | KRON | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1826766 | Christopher Dinsmore | C/O Kronos Bio, Inc. 1300 So. El Camino Real, Suite 400 San Mateo CA 94402 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-01-04 | 7,366 | $1.18 | 260,969 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units.
- The weighted average sale price for the transaction reported was $1.1836, and the range of prices were between $1.12 to $1.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Billionaire Hedge Funds
